Skip to main content

Mineralys Therapeutics, Inc 8-K, filed Oct 29, 2026

Mineralys Therapeutics, Inc. (MLYS)

8-K 2026-10-29 For: 2026-10-27
View Original
Added on October 29, 2026

About this 8-K

Mineralys Therapeutics, Inc filed this 8-K on October 29, 2026, reporting on events of October 27, 2026.

Mineralys Therapeutics, Inc. terminated its lorundrostat license with Tanabe Pharma Corporation on October 27, 2026, received related patents and know-how, and retained milestones of up to $255.0 million plus $10.0 million for a potential second indication. AI summary

Items reported

  • Item 1.01: Entered into a material agreement
  • Item 1.02: Ended a material agreement